Education
About Us
Working with TipRanks
Follow Us
Biomarin Pharmaceutical Inc. (BMRN)
:BMRN
RESEARCH TOOLSreports
BMRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$60.63 - $94.85
Previous CloseN/A
Volume465.01K
Average Volume (3M)1.69M
Market Cap
$13.01B
Enterprise Value$13.54B
Total Cash (Recent Filing)$493.98M
Total Debt (Recent Filing)$830.42M
Price to Earnings (P/E)31.1
Beta0.47
Next Earnings
Apr 23, 2025EPS Estimate
0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.19
Shares Outstanding190,583,020
10 Day Avg. Volume1,586,064
30 Day Avg. Volume1,694,010
Standard Deviation0.09
R-Squared0.03
Alpha-0.00358
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)N/A
Price to Sales (P/S)4.73
Price to Cash Flow (P/CF)14.70
P/FCF Ratio16.20
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.95
Enterprise Value/Ebitda26.68
Forecast
1Y Price Target
$99.05Price Target Upside43.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBMRN beat expectations by reporting total sales of $747M in 4Q24 which is higher than projections of $712/$708M that represents a +16% YoY growth.
Product GrowthManagement delivered impressive 56% YoY Voxzogo growth driven by expanding prescriber base and increasing penetration in the U.S. and other markets.
Bears Say
Legal RisksPotential legal action against ASND on Voxzogo IP could impact product deployment in multiple EU countries.
---
Ownership Overview
0.95% Insiders
36.73% Mutual Funds
0.42% Other Institutional Investors
39.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMRN FAQ
What was Biomarin Pharmaceutical Inc.’s price range in the past 12 months?
Biomarin Pharmaceutical Inc. lowest stock price was $60.63 and its highest was $94.85 in the past 12 months.
What is Biomarin Pharmaceutical Inc.’s market cap?
Biomarin Pharmaceutical Inc.’s market cap is $13.01B.
When is Biomarin Pharmaceutical Inc.’s upcoming earnings report date?
Biomarin Pharmaceutical Inc.’s upcoming earnings report date is Apr 23, 2025 which is in 55 days.
How were Biomarin Pharmaceutical Inc.’s earnings last quarter?
Biomarin Pharmaceutical Inc. released its earnings results on Feb 19, 2025. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.534 by $0.106.
Is Biomarin Pharmaceutical Inc. overvalued?
According to Wall Street analysts Biomarin Pharmaceutical Inc.’s price is currently Undervalued.
Does Biomarin Pharmaceutical Inc. pay dividends?
Biomarin Pharmaceutical Inc. does not currently pay dividends.
What is Biomarin Pharmaceutical Inc.’s EPS estimate?
Biomarin Pharmaceutical Inc.’s EPS estimate is 0.7.
How many shares outstanding does Biomarin Pharmaceutical Inc. have?
Biomarin Pharmaceutical Inc. has 190,583,020 shares outstanding.
What happened to Biomarin Pharmaceutical Inc.’s price movement after its last earnings report?
Biomarin Pharmaceutical Inc. reported an EPS of $0.64 in its last earnings report, beating expectations of $0.534. Following the earnings report the stock price went up 4.755%.
Which hedge fund is a major shareholder of Biomarin Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in BMRN
---
BioMarin Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.05 (43.95% Upside)
$99.05 (43.95% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $350.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.62%
12-Months-Change
Fundamentals
Return on Equity
8.05%
Trailing 12-Months
Asset Growth
2.15%
Trailing 12-Months
Company Description
Biomarin Pharmaceutical Inc.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
---
BMRN Company Deck
---
BMRN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for BioMarin highlighted strong financial growth and strategic advancements, particularly in VOXZOGO's expansion and enzyme therapy sales. Despite some expected reductions in growth rates for certain enzyme products and increased SG&A expenses, the overall sentiment remains positive due to strong revenue growth, expanded profitability, and promising future outlook.Read More>---
BMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BMRN Stock 12 Month Forecast
Average Price Target
$99.05
▲(43.95% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering BMRN
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
-1.51%
reiterated a buy rating 9 days ago
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.51% per trade.
---